[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.5.192. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 763
Citations 0
Editorial
December 28, 2016

Troponin Assessment in Heart Failure With Preserved Ejection FractionTime to Get With the Guidelines

Author Affiliations
  • 1Section of Cardiology, University of Chicago, Chicago, Illinois
JAMA Cardiol. Published online December 28, 2016. doi:10.1001/jamacardio.2016.4840

Over the past 2 decades, heart failure has become the leading cause of cardiovascular morbidity and mortality. Epidemiological studies show that approximately half of the patients diagnosed with heart failure have a normal ejection fraction.1 The combination of an aging population along with a marked increase in the prevalence of comorbid conditions has resulted in a steady increase in the diagnosis of heart failure with preserved ejection fraction (HFpEF). Compared with patients with left ventricular dysfunction, patients with HFpEF appear to have better survival, although mortality remains significantly higher than that of the healthy population.2 Of equal concern is the high rate of morbidity and frequent hospital admissions associated with HFpEF.3 Despite multiple large-scale clinical trials, no study has identified a treatment that can improve overall survival.46

First Page Preview View Large
First page PDF preview
First page PDF preview
×